By Doug Macron
Spanish RNAi drug shop Sylentis expects to dose the first patient in a phase I study of its glaucoma-associated ocular hypertension drug SYL040012 in Spain around the end of September, a company official confirmed to RNAi News this week.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
